-
Tytuł:
-
Immunotherapy in gastrointestinal cancer: The current scenario and future perspectives.
-
Autorzy:
-
Abdul-Latif M; Department of Oncology, North Middlesex University Hospital, Sterling Way, London N18 1QX, United Kingdom.
Townsend K; The Royal Marsden, Fulham Road, London SW3 6JJ, United Kingdom.
Dearman C; The Royal Marsden, Fulham Road, London SW3 6JJ, United Kingdom.
Shiu KK; Department of Medical Oncology, University College London Cancer Institute, 72 Huntly St., Fitzrovia, London WC1E 6AG, United Kingdom.
Khan K; Department of Oncology, North Middlesex University Hospital, Sterling Way, London N18 1QX, United Kingdom; Department of Medical Oncology, University College London Cancer Institute, 72 Huntly St., Fitzrovia, London WC1E 6AG, United Kingdom. Electronic address: .
-
Źródło:
-
Cancer treatment reviews [Cancer Treat Rev] 2020 Aug; Vol. 88, pp. 102030. Date of Electronic Publication: 2020 May 28.
-
Typ publikacji:
-
Journal Article; Review
-
Język:
-
English
-
Imprint Name(s):
-
Publication: 2003- : Amsterdam : Elsevier
Original Publication: London, New York, Academic Press.
-
MeSH Terms:
-
Gastrointestinal Neoplasms/*therapy
Immunotherapy/*methods
Animals ; Antineoplastic Agents, Immunological/administration & dosage ; Cancer Vaccines/administration & dosage ; Gastrointestinal Neoplasms/immunology ; Humans ; Immunotherapy, Adoptive/methods ; Randomized Controlled Trials as Topic
-
Contributed Indexing:
-
Keywords: Adoptive cell therapy; Biliary; Checkpoint inhibition; Colorectal; Gastric; Gastrointestinal cancer; Hepatic; Immunotherapy; Oesophageal; Pancreatic; Review; Vaccine
-
Substance Nomenclature:
-
0 (Antineoplastic Agents, Immunological)
0 (Cancer Vaccines)
-
Entry Date(s):
-
Date Created: 20200608 Date Completed: 20200729 Latest Revision: 20200729
-
Update Code:
-
20240104
-
DOI:
-
10.1016/j.ctrv.2020.102030
-
PMID:
-
32505807
-
Gastrointestinal cancers include colorectal, gastric, oesophageal, pancreatic and liver cancers. They continue to be a significant cause of mortality and morbidity worldwide. Current treatment strategies include chemotherapy, surgery, radiotherapy and targeted therapies. Immunotherapy has recently been incorporated in treatment regimens for some gastrointestinal malignancies and research into different immune modifying treatments is being carried out in this context. Approaches to immune modulation such as vaccination, adoptive cell therapy and checkpoint inhibition have shown varying clinical benefit, with most of the benefit seen in checkpoint inhibition. This review summarises recent advances and future direction of immunotherapy in patients with gastrointestinal malignancies.
Competing Interests: Declaration of Competing Interest The authors declared that there is no conflict of interest.
(Copyright © 2020 Elsevier Ltd. All rights reserved.)
